Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY 10065, USA; Tri-Institutional Program in Computational Biology and Medicine, The Rockefeller University, New York, NY 10065, USA.
Laboratory of Systems Cancer Biology, The Rockefeller University, New York, NY 10065, USA; Department of Pathology and Laboratory of Medicine, Department of Neuroscience, South Carolina Alzheimer's Disease Research Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Immunity. 2024 Jan 9;57(1):153-170.e6. doi: 10.1016/j.immuni.2023.12.001. Epub 2023 Dec 29.
The dominant risk factors for late-onset Alzheimer's disease (AD) are advanced age and the APOE4 genetic variant. To examine how these factors alter neuroimmune function, we generated an integrative, longitudinal single-cell atlas of brain immune cells in AD model mice bearing the three common human APOE alleles. Transcriptomic and chromatin accessibility analyses identified a reactive microglial population defined by the concomitant expression of inflammatory signals and cell-intrinsic stress markers whose frequency increased with age and APOE4 burden. An analogous population was detectable in the brains of human AD patients, including in the cortical tissue, using multiplexed spatial transcriptomics. This population, which we designate as terminally inflammatory microglia (TIM), exhibited defects in amyloid-β clearance and altered cell-cell communication during aducanumab treatment. TIM may represent an exhausted-like state for inflammatory microglia in the AD milieu that contributes to AD risk and pathology in APOE4 carriers and the elderly, thus presenting a potential therapeutic target for AD.
晚期阿尔茨海默病 (AD) 的主要危险因素是年龄较大和 APOE4 遗传变异。为了研究这些因素如何改变神经免疫功能,我们生成了一个整合的、纵向的 AD 模型小鼠大脑免疫细胞单细胞图谱,这些小鼠携带三种常见的人类 APOE 等位基因。转录组和染色质可及性分析确定了一个由炎症信号和细胞内应激标志物同时表达定义的反应性小胶质细胞群体,其频率随年龄和 APOE4 负担的增加而增加。使用多重空间转录组学,在人类 AD 患者的大脑中,包括皮质组织中,都可以检测到类似的群体。我们将这个群体命名为终末炎症小胶质细胞 (TIM),在 aducanumab 治疗期间,TIM 表现出清除淀粉样蛋白-β的缺陷和改变的细胞间通讯。TIM 可能代表了 AD 环境中小胶质细胞的耗尽样状态,它导致了 APOE4 携带者和老年人的 AD 风险和病理学,因此为 AD 提供了一个潜在的治疗靶点。